Mylan Gets Teva's Copaxone Patent Invalidated By UK Court
The U.K. High Court of Justice said Thursday one of Teva Pharmaceutical Industries Ltd.'s patents covering the multiple sclerosis drug Copaxone is invalid as obvious, paving the way for Mylan NV...To view the full article, register now.
Already a subscriber? Click here to view full article